Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00425061 | Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma | PHASE2 | COMPLETED | 159 | — | — | Feb 1, 2007 | Aug 1, 2008 | Jan 14, 2015 | 82 | United States, Canada |
| NCT00339872 | Study Evaluating IMA-638 in Asthma | PHASE1 | COMPLETED | - | — | — | Feb 1, 2006 | Apr 1, 2007 | Dec 5, 2007 | 1 | United States |
The PEFR is a participant's maximum speed of expiration, as measured with a peak flow meter. All participants were issued with the peak flow meter and instructed to perform the activity in triplicate in the morning prior to taking bronchodilator. The best among the 3 readings was selected.
The PEFR is a participant's maximum speed of expiration, as measured with a peak flow meter. All participants were issued with the peak flow meter and instructed to perform the activity in triplicate in the morning prior to taking bronchodilator. The best among the 3 readings was selected.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IMA-638 | BIOLOGICAL | SC Injection, 12 weeks |
| placebo | OTHER | placebo |
Inclusion Criteria: * Generally healthy men and women with persistent asthma, 18 to 70 years of age, with body weight between 50 kg and 115 kg. * History of treatment with a medium to high dose of inhaled corticosteroids (ICS), with or without long-acting beta-agonists (LABA), for at least 2 months...